by dermatologists were more likely to receive surgery subsequently (p ϭ 0.002). Older age and female gender were associated with a lower likelihood to receive surgery, systemic, or radiation therapy. CONCLUSIONS: Sites of metastases and treating physician specialty might influence treatments for patients with metastatic melanoma. 
PCN139 BLOOD TRANSFUSION UTILIZATION IN CHEMOTHERAPY-INDUCED ANEMIA-AN ANALYSIS OF HOSPITAL INPATIENT AND OUTPATIENT RECORDS IN THE UNITED STATES
Forlenza
OBJECTIVES:
This retrospective analysis of US hospital inpatient and outpatient electronic records aimed to describe current blood transfusion utilization in a population with chemotherapy-induced anemia (CIA). METHODS: The Premier Hospital Database (2006 Database ( -2010 was used to identify records for cancer patients aged 18 years or older who had received chemotherapy and a diagnosis of anemia (ICD9 codes: 284.x, 285.3, and 285.9) . Excluded were those who received renal dialysis or had a diagnosis of chronic kidney disease, myeloid cancer, myelodysplastic syndrome, or anemia due to chronic illnesses. The study population was then categorized into three subgroups based on ICD-9 procedure codes, CPT codes, and billing code descriptions in the database within the same month as or two months after the anemia diagnosis: 1) The Blood Transfusion group had either ICD-9 codes, CPT codes, or a select subset of billing code descriptions specific to blood transfusion; 2) The Other/unknown Transfusion group had only billing code descriptions that appeared to be transfusion-related but were non-specific; and 3) The No Transfusion group had no transfusion-related ICD-9 codes, CPT codes, or billing code descriptions. RESULTS: During the 5 years of data, there were 2980-7094 CIA occurrences in a given year. Average age for the CIA population ranged from 60-62 years and 52%-55% were female. During the years observed, the Blood Transfusion group comprised 44-51% of the total CIA study population. When other transfusion codes were considered (Blood Transfusion population plus Other/unknown Transfusion population), this number increased to 56-61% of the total CIA study population. CONCLUSIONS: These results from five years of hospital inpatient and outpatient records suggest that there is a large portion of CIA patients that may be receiving blood transfusions. Further research to better understand the characteristics of CIA patients receiving blood transfusions and blood utilization in this population is warranted. 
PCN140 MANAGING THE RISK OF EXPOSURE TO LOW-IONIZING RADIATION IN CANADA: A POPULATION MODEL

OBJECTIVES:
Rapidly increasing use of imaging procedures in Canada and the United States has raised concerns about exposure to low-dose ionizing radiation in the general population. We assessed radiation exposure from medical and nonmedical uses. METHODS: Recent evidence-based studies linked exposure to lowdose, ionizing radiation with the development of cancer/leukemia. Individuals at risk for repeated radiation exposure (in health care/nuclear industry) are typically monitored and restricted to effective doses of 20-50 mSv per year. In contrast, radiation exposure in the general population is not monitored. Using the epidemiological databases from Canada and the United States, we are developing an age/ sex stratified population model to assess radiation exposure from medical and non-medical uses. We identify the potentially most exposed subpopulations, for which the long-term risks are most relevant. RESULTS: We compiled the list of effective doses (mSv) from radiation exposure for common medical and non-medical uses, using National Council on Radiation Protection and Measurement (NCRP) data and other published sources. Excluding naturally occurring radiation, most of radiation comes from medical use as opposed to non-medical use. In medical use, the bulk of exposure is related to CT and nuclear imaging, especially cardiac. Exposure to nuclear medicine examinations among 65ϩ individuals is 3 times higher than among 30-44 group, fast growing over time, with higher exposure among females than males. Concern is emerging about rapidly increasing doses among pediatric populations. In non-medical use exposure is minor, coming mainly from cigarette smoking, building materials, and commercial air travel. Results are presented by age and sex, and sensitivity analyses on selected variables are reported. CONCLUSIONS: Given the rapidly growing radiation exposure, our findings might have important implications for the health of the general population. Strategies to monitor and to manage cumulative exposure, especially in medical use in the general population should be developed. 
PCN141 PROJECTING THE POTENTIAL PUBLIC HEALTH IMPACT OF A 9-VALENT HPV VACCINE IN THE UNITED STATES
OBJECTIVES:
To project the potential public health impact of a 9-valent HPV vaccine in the United States. METHODS: A previously published non-linear, deterministic compartmental model of HPV (6, 11, 16, and 18) transmission was extended to include HPV 31, 33, 45, 52, and 58. We calibrated the model to US epidemiological data on cervical cancer, attributing 70% of cervical cancer to HPV 16 and 18, and 20 % to HPV 31, 33, 45, 52, and 58 . Other inputs were from public data sources and published literature. Because it is currently unavailable, vaccine efficacy against 5 additional HPV types was assumed to be similar to that of the quadrivalent vaccine (HPV4) against HPV 16. We assessed the impact of 9-valent HPV vaccination (HPV9) relative to current US HPV4 recommendations, with routine vaccination for 11-12 year olds and a permanent catch-up program for 13-26 year old females and 13-18 year old males, and coverage of 80% for females and 48% for males, with 50% of vaccinees receiving all doses of the vaccine. RESULTS: We project that HPV9 vaccination of males and females will reduce the incidence of cervical cancer by 63% over 100 years, relative to 52% for HPV4. HPV9 vaccination relative to HPV 4 vaccination prevents an additional 872,000 cases of CIN1 (Cervical Intraepithelial Neoplasia), 1,881,000 cases of CIN2/3, and 80,000 cases of cervical cancer in the US population, cumulative over 100 years. CONCLUSIONS: Protecting the population against HPV infection with an HPV9 vaccination program relative to an HPV4 vaccination program can have significant public health benefits.
